GlaxoSmithKline

Datacubed Health Announces New Board Member, Mark Blumling

Retrieved on: 
Wednesday, February 8, 2023

New York, New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Datacubed Health, a leading eClinical technology company, is proud to announce the appointment of Mark Blumling to its Board of Directors.

Key Points: 
  • New York, New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Datacubed Health, a leading eClinical technology company, is proud to announce the appointment of Mark Blumling to its Board of Directors.
  • “We are thrilled to welcome Mark to our Board,” said Brett Kleger, CEO of Datacubed Health.
  • He is excited to bring his experience and insights to Datacubed Health and help the company continue to make a positive impact on the healthcare industry.
  • “I am honored to join the Datacubed Health team and am excited to contribute my experience and insights to the company’s mission of advancing access to healthcare through innovative clinical technology solutions,” said Mark Blumling.

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Retrieved on: 
Wednesday, January 18, 2023

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.

Key Points: 
  • TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.
  • as the Company’s Chief Medical Officer, effective immediately.
  • Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company.
  • Second, the Company’s strong intellectual property position gives Reunion a significant competitive advantage over others in the space,” added Dr. Alexander.

Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development

Retrieved on: 
Wednesday, January 18, 2023

BURLINGAME, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the expansion of its senior management team, which is expected to drive the Company’s GEM-DIMER™ programs, with an initial focus in oncology, to clinical development. Harold E. “Barry” Selick, Ph.D., a successful and distinguished biopharmaceutical scientist, senior executive and venture investor, was named as Chief Executive Officer. Carin Rollins, a Company co-founder, becomes Chief Operating Officer. Joshua Carle, an experienced business development executive from both the buy-side and sell-side, joins the Company as Chief Business Officer.

Key Points: 
  • Joshua Carle, experienced business development and R&D investment executive, appointed Chief Business Officer
    BURLINGAME, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company, today announced the expansion of its senior management team, which is expected to drive the Company’s GEM-DIMER™ programs, with an initial focus in oncology, to clinical development.
  • Harold E. “Barry” Selick, Ph.D., a successful and distinguished biopharmaceutical scientist, senior executive and venture investor, was named as Chief Executive Officer.
  • Joshua Carle, an experienced business development executive from both the buy-side and sell-side, joins the Company as Chief Business Officer.
  • “Now is the time to add executives who can accelerate the clinical and business development activities of our powerful GEM-DIMER platform.

Breast Cancer Therapeutics Market is expected to generate a revenue of USD 53.72 Billion by 2030, Globally, at 8.3% CAGR: Verified Market Research®

Retrieved on: 
Thursday, January 19, 2023

JERSEY CITY, N.J., Jan. 19, 2023 /PRNewswire/ -- Verified Market Research® recently published a report, "Breast Cancer Therapeutics Market" By Drug Class (HER2 Inhibitors, Mitotic Inhibitors), By Therapy (Chemotherapy, Radiation Therapy), and By Geography.

Key Points: 
  • Due to the rising incidence of the condition, especially in developed nations, which will fuel the expansion of the Breast Cancer Therapeutics Market, the Global Breast Cancer Therapeutics Market is anticipated to witness exceptional growth in the future years.
  • The "Global Breast Cancer Therapeutics Market" is mainly bifurcated into sub-segments which can provide classified data regarding the latest trends in the market.
  • The "Global Breast Cancer Therapeutics Market" study report will provide valuable insight with an emphasis on the global market.
  • Based on the research, Verified Market Research® has segmented the global Breast Cancer Therapeutics Market into Drug Class, Therapy, and Geography.

Global TCR Therapy Market 2022 to 2035: Distribution by Target Indication, Target Antigen, Key Players and Geographies - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

The "Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TCR Therapy Market, 2022-2035: Distribution by Target Indication, Target Antigen, Key Players and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers.
  • Modified T-cell receptor therapy (TCR therapy), an upcoming class of cell-based interventions, is a promising therapeutic modality.
  • Overall, we are led to believe that the global TCR therapy market is poised to witness significant growth in the foreseen future.

Global Generic Drugs Market to Grow by $176.25 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

This study identifies the advent of RPA as one of the prime reasons driving the generic drugs market growth during the next few years.

Key Points: 
  • This study identifies the advent of RPA as one of the prime reasons driving the generic drugs market growth during the next few years.
  • Also, rising m and a and hospital-owned generics will lead to sizable demand in the market.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Expansion of AESARA Europe with the Appointment of Italian pharmaceutical industry veteran, Patrizia Berto

Retrieved on: 
Thursday, January 12, 2023

AESARA ( www.aesara.com ) is delighted to announce the appointment of industry veteran value & access strategist Patrizia Berto PharmD, MBA, to the European Strategic Partnerships team.

Key Points: 
  • AESARA ( www.aesara.com ) is delighted to announce the appointment of industry veteran value & access strategist Patrizia Berto PharmD, MBA, to the European Strategic Partnerships team.
  • Based in Italy, within the AESARA Europe team, Patrizia will bring: depth of insight into the Italian market; a broader European perspective on health technology assessment (HTA), pricing & reimbursement; and globally-applicable technical expertise in health economics and outcomes research (HEOR).
  • Gavin Outteridge, Managing Director of AESARA Europe said, “I am thrilled to be able to connect Patrizia to AESARA’s clients.
  • I hope to teach some, to learn a lot and to put all my experience at the service of AESARA’s clients,” said Patrizia Berto on her appointment as Principal, AESARA Europe.

Global Chronic Obstructive Pulmonary Disease Drugs Market to Grow by $66.54 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.

Key Points: 
  • This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years.
  • Also, advances in drug delivery devices and the growing use of e-cigarettes and other products for people to quit smoking will lead to sizable demand in the market.
  • The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Global Active Pharmaceutical Ingredients (APIs) Market Analysis/Forecast Report, 2022 & 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredients (APIs) Market, Global Forecast 2023-2027, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Active Pharmaceutical Ingredients (APIs) market was at US$ 190.5 Billion in 2022 and will surpass US$ 261.3 Billion by 2027, expanding at a CAGR of 6.52 from 2022 to 2027.
  • Active Pharmaceutical Ingredients (API) of good quality is core to manufacturing effective and safe essential drugs.
  • Some prominent players in the global active pharmaceutical ingredients market are Sanofi SA, F. Hoffmann-LA Roche Ltd, Pfizer, Abbott, Bayer AG, Merck & Co. Inc, Boehringer Ingelheim Gmbh, GlaxoSmithKline Plc, Novartis AG, Eli Lilly Company, and Teva Pharmaceutical.

Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP

Retrieved on: 
Tuesday, January 10, 2023

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Murray W. Stewart, D.M., F.R.C.P., has been appointed to the Company’s Board of Directors. Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70 percent of new independent directors who were named to the Board over the last 12 months.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Murray W. Stewart, D.M., F.R.C.P., has been appointed to the Company’s Board of Directors.
  • Following the appointment of Dr. Stewart, the Amarin Board will be made up of approximately 70 percent of new independent directors who were named to the Board over the last 12 months.
  • “As we focus on launching in Europe and diversifying our product portfolio, adding Dr. Stewart to our Board brings exceptional expertise in cardiometabolic research and clinical development,” said Per Wold-Olsen, Chairman of the Board of Directors, Amarin.
  • As part of the Company’s focus on stronger corporate governance, Amarin has named six new members to the Company’s board of directors over the last 12 months, including Dr. Murray Stewart.